Integrated Investment Consultants »

Regeneron Pharmaceuticals shares owned by Integrated Investment Consultants

Quarter-by-quarter ownership of Regeneron Pharmaceuticals (REGN) shares owned by Integrated Investment Consultants from 13F filings

Historical chart of Integrated Investment Consultants investment in Regeneron Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Regeneron Pharmaceuticals held by Integrated Investment Consultants consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Regeneron Pharmaceuticals by Integrated Investment Consultants

Quarter filed Position value Share count Share price at filing
2024-03-31 $296k 308 962.49
2018-06-30 $9.0k 25 360.00
2018-03-31 $8.0k 22 363.64
2017-09-30 $999 3 333.33

More positions owned by Integrated Investment Consultants

Ishares Russell 1000 Growth Etf Etf (IWF)
Ishares Russell Mid-cap Growth Etf Etf (IWP)
Schwab Charles Family Fd Amt Tax Free Mny Money Market Fund (SCTXX)
Ishares Russell 1000 Value Etf Etf (IWD)
Schwab Us Dividend Equity Etf Etf (SCHD)
Ishares Core Msci Eafe Etf Etf (IEFA)
Vanguard Ftse Developed Markets Etf Etf (VEA)
Microsoft Corp Stock (MSFT)
Vanguard Russell 1000 Growth Etf Etf (VONG)
Ishares Core S&p 500 Etf Etf (IVV)
Apple Stock (AAPL)
Ishares Morningstar Mid-cap Growth Etf Etf (IMCG)
Ishares Intermediate Government/credit Bond Etf Etf (GVI)
Schwab U.s. Large-cap Growth Etf Etf (SCHG)
Vanguard Value Etf Etf (VTV)

View all positions for Integrated Investment Consultants

Top funds holding Regeneron Pharmaceuticals

Vanguard Group
Jpmorgan Chase & Co
Dodge & Cox
Wellington Management Company
Norges Bank Investment Management
Legal & General Group
Bank of America Corporation
Amundi
Bank of New York Mellon
Citadel Advisors
Alliancebernstein
T. Rowe Price Associates
Ubs Global Asset Management Americas
Charles Schwab Investment Management
Dimensional Fund Advisors

View all funds holding Regeneron Pharmaceuticals